Predictive value of LCP1 and ADPGK for immune-related adverse events across multiple cancer types in patients receiving immunotherapy-based regimens
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have transformed oncology but are frequently compromised
Authors
- Junhua Li (ORCID: https://orcid.org/0000-0002-9611-9801)
- Y. Bai (ORCID: https://orcid.org/0009-0009-5533-5688)
- Xueqin Zeng
- Dongzi Pang
- Wei Sun
- Shuqing Wei
- Xi Zhang
- Fan Zhang
- Yaqian Li
- Dan Xue
- Xing Gou
- Hongyu Liu
- Li Zhang
- Jing Zhang
Institutions
- Shanxi Medical University (CN)
- Renji Hospital (CN)
- Beijing Founder Electronics (China) (CN)
- Shanxi Provincial Cancer Hospital (CN)
- Cancer Hospital of Chinese Academy of Medical Sciences (CN)
Publication Details
- Journal
- Acta Biochimica et Biophysica Sinica
- Published
- 2026-02-01
- DOI
- https://doi.org/10.3724/abbs.2026016
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wu Jieping Medical Foundation